Possibilities of using anti-cytokine drugs for inflammatory dermatoses in HIV-positive patients


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The use of anticytokine drugs for the reversible blocking of an overproduction of certain cytokines is a highly promising direction in medicine. In particular, the use of targeted therapy for inflammatory dermatoses requiring systemic treatment is also in this direction. At the same time, the immunological features of the course of inflammatory dermatoses in HIV-infected patients remain a poorly studied issue. The review article analyzes the identified immunological features in patients with inflammatory dermatoses (psoriasis, atopic dermatitis, seborrheic dermatitis) with HIV infection, describes possible common points of application of modern biological drugs aimed at treating inflammatory dermatoses, taking into account the possible impact on the course of HIV infection. In addition, the authors ask about the effect of the ongoing anticytokine therapy of autoimmune dermatoses in HIV-infected patients on a possible change in the sensitivity and effectiveness of antiretroviral therapy in this category of patients. It is known that from 5 to 30% of HIV-infected patients practically do not respond to antiretroviral therapy. As an example of the effectiveness of the treatment of inflammatory dermatoses, the experience of using interleukin blockers in a limited number of foreign publications is presented.

Texto integral

Acesso é fechado

Sobre autores

Evgeny Evdokimov

Central Research Institute of Epidemiology

Email: evdokimovevg@yandex.ru
Cand. Sci. (Med.), Researcher at the Clinical Department Moscow, Russia

Zh. Ponezheva

Central Research Institute of Epidemiology

Moscow, Russia

E. Svechnikova

Polyclinic №1 of the Administrative Department of the President of the Russian Federation; Novosibirsk State Medical University

Moscow, Russia

A. Sundukov

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Moscow, Russia

Bibliografia

  1. Garg Т., Sanke S. Inflammatory dermatoses In human immunodeficiency virus. Indian J Sex Transm Dis AIDS. 2017;38(2):113-20. doi: 10.4103/ijstd.IJSTD_22_17.
  2. Ceccarelli M., Rullo E.V., Vaccaro M., et al. HIV associated psoriasis: EpidemiologY., pathogenesis, and management. Dermatologic Therapy. 2019;32:e12806. doi: 10.1111/dth.12806.
  3. Атопический дерматит и экзематозные расстройства. Под ред. Д. Рудикоффа, С.Р Коэна, Н. Шайнфельда. Пер. с англ. под ред. Н.Н. Потекаева, А.Н. Львова. М.: ГЭОТАР-Медиа, 2017. 384 с.
  4. Fernandes S., Pinto G.M., Cardoso J. Particular clinical presentations of psoriasis in HIV patients. Int J STD AIDS. 2011;22:653-54. Doi: 10.1258/ ijsa.2011.010525.
  5. Queirosa N., Torresab T. HIV-associated psoriasis Psoriasis asociada a VIH. Actas Dermo-Sifiliogra ficas (English Edition). 2018;109(4):303-11. doi: 10.1016/j.adengl.2018.02.020.
  6. Дерматология Фицпатрика в клинической практике. Под ред. Л.А. Голдсмит, С.И. Кац, Б.А. Джилкрест и др. Пер. с англ. Под ред. Н.Н. Потекаева, А.Н. Львова. М., 2015. Т. 1. 1168 с.: ил.
  7. Matejuk A. Skin Immunity Arch Immunol Ther Exp (Warsz). 2018;66(1):45-54. Doi: 10.1007/ s00005-017-0477-3.
  8. Agrawal R., Wisniewski J.A., Woodfolk J.A. The role of regulatory T cells in atopic dermatitis. Curr Probl Dermatol. 2011;41:112-24. doi: 10.1159/000323305.
  9. Singh R., Heron C.E., Ghamrawi R.I., et al. Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis. Immunotargets Ther.2020;9:255-72. doi: 10.2147/ITT.S229667.
  10. Pace B.T., Lackner A.A., Porter E., Pahar B. The Role of Defensins in HIV Pathogenesis. Mediators Inflamm. 2017;2017:5186904. doi: 10.1155/2017/5186904.
  11. Ogawa Y., Kawamura T., Matsuzawa T., et al. Antimicrobial Peptide LL-37 Produced by HSV-2-Infected Keratinocytes Enhances HIV Infection of Langerhans Cells. Cell Host Microbe. 2013;13(1):77-86. Doi: 10.1016/j. chom.2012.12.002.
  12. Sonaimuthu B., Baghyanathan V. Study on the functional role of immunoglobulin E as surrogate marker for HIV/AIDS infection. Retrovirology. 2012;9:P96. doi: 10.1186/1742-4690-9-S2-P96.
  13. Абрамовитс У., Акхаван А., Альтчек Д., и др. Под ред. Д. Рудикоффа и др. Атопический дерматит и экзематозные расстройства. Пер. с англ. Под ред. Н.Н. Потекаева, А.Н. Львова. М.: ГЭОТАР-Медиа, 2017. 384 с.
  14. Altman K., Vanness E., Westergaard R.P. Cutaneous manifestations of human immunodeficiency virus: a clinical update. Curr Infect Dis Rep. 2015;17(3):464. doi: 10.1007/s11908-015-0464-y.
  15. Saison J., Maucort Boulch D., Chidiac C., et al. Increased Regulatory T-Cell Percentage Contributes to Poor CD4+ Lymphocytes Recovery: A 2-Year Prospective Study After Introduction of Antiretroviral Therapy Open Forum Infect Dis. 2015;2(2):ofv063. doi: 10.1093/ofid/ofv063.
  16. Deckers J., Hammad H., Hoste E. Langerhans Cells: Sensing the Environment in Health and Disease. Front Immunol. 2018;9:93. Doi: 10.3389/ fimmu.2018.00093.
  17. Matsuzawa T., Ogawa Y., Moriishi K., et al. Immunological function of Langerhans cells in HIV infection. J Dermatol Sci. 2017;87(2):159-67.
  18. Reuter M.A., Pombo C., Betts M.R. Cytokine production and dysregulation in HIV pathogenesis: Lessons for development of therapeutics and vaccines. Cytokine Growth Factor Rev. 2012;23(4-5):181-91. doi: 10.1016/j.cytogfr. 2012.05.005.
  19. Tampa M., Sarbu M.I., Mitran M.I., et al. The Pathophysiological Mechanisms and the Quest for Biomarkers in Psoriasis, a Stress-Related Skin Disease. Dis Markers. 2018;2018:5823684. doi: 10.1155/2018/5823684.
  20. Lowes M.A., Suarez-Farinas M., Krueger J.G. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-55. doi: 10.1146/annurev-immunol-032713-120225.
  21. Nograles K.E., Zaba L.C., Guttman-Yassky E., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092-102. doi: 10.1111/j.1365-2133.2008.08769.x.
  22. Chen M., Dai S.M. A novel treatment for psoriatic arthritis: Janus kinase inhibitors. Chin Med J (Engl). 2020; 133(8):959-67. Doi: 10.1097/ CM9.0000000000000711.
  23. Kwatra S.G., Dabade T.S., Gustafson C.J., Feldman S.R. JAK inhibitors in psoriasis: a promising new treatment modality. J Drugs Dermatol. 2012;11(8):913-18.
  24. Iketleng T., Moyo S., Gaseitsiwe S., et al. Plasma Cytokine levels in Chronic Asymptomatic HIV-1 Subtype C Infection as an Indicator of Disease Progression in Botswana: A Retrospective Case Control Study AIDS Res Hum Retroviruses. 2016;32(4):364-69. Doi: 10.1089/ AID.2015.0163.
  25. Guo H., Gao J., Taxman D.J., et al. HIV-1 infection induces interleukin- 1ß production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes. J Biol Chem. 2014;289(31):21716-26. doi: 10.1074/jbc. M114.566620.
  26. Brandner J.M., Zorn-Kruppa M., Yoshida T., et al. Epidermal tight junctions in health and disease. Tissue Barriers. 2015;3(1-2):e974451. doi: 10.4161/21688370.2014.974451.
  27. Aziz N., Detels R., Chang L.C., Butch A.W. Macrophage Inflammatory Protein-3 Alpha (MIP-3a)/CCL20 in HIV-1-lnfected Individuals. J AIDS Clin Res. 2016;7(7):587. doi: 10.4172/21556113.1000587.
  28. Garg A., Rawat P., Spector S.A. Interleukin 23 produced by myeloid dendritic cells contributes to T-cell dysfunction in HIV type 1 infection by inducing SOCS1 expression. J Infect Dis. 2015;211(5):755-68. doi: 10.1093/infdis/jiu523.
  29. Quan Y., Xu H., Han Y., et al. JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1. J Virology. 2017;91(9):e00075-17. Doi: 10.1128/ JVI.00075-17.
  30. Haile W.B., Gavegnano C., Tao S., et al. The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol Dis. 2016;92(Pt B):137-43. Doi: 10.1016/j. nbd.2016.02.007.
  31. Spivak A.M., Larragoite E.T., Coletti M.L. et al. Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo. Retrovirology. 2016;13:88. Doi: 10.1186/ s12977-016-0319-0.
  32. Евдокимов Е.Ю., Сундуков А.В., Горелова Е.А. Роль кожной и кишечной микробиоты у ВИЧ-инфицированных больных в патогенезе некоторых заболеваний кожи. Эпидемиология и инфекционные болезни актуальные вопросы. 2019;9( 1 ):107-14.
  33. Saxena D., Li Y., Yang L., et al. Human microbiome and HIV/AIDS. Curr HIV/AIDS Rep. 2012;9(1):44-doi: 10.1007/s11904-011-0103-7.
  34. Park Y.J., Lee H.K. The Role of Skin and Orogenital Microbiota in Protective Immunity and Chronic Immune-Mediated Inflammatory Disease. Front Immunol. 2018;8:1955. Doi: 10.3389/ fimmu.2017.01955.
  35. Elhed A., Unutmaz D. Th17 cells and HIV infection. Curr Opin HIV AIDS. 2010;5(2):146-50. doi: 10.1097/COH.0b013e32833647a8.
  36. Yannam G.R., Gutti T., Poluektova L.Y. IL-23 in Infections, Inflammation, Autoimmunity and Cancer: Possible Role in HIV-1 and AIDS. J Neuroimmune Pharmacol. 2012;7:95-112. doi: 10.1007/s11481-011-9315-2.
  37. Bartos G., Cline A., Beroukhim K., et al. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. Dermatol Online J. 2018;24(11):13030/ qt3db748cg.
  38. Bardazzi F., Magnano M., Campanati A., et al.Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience. Acta Derm Venereol. 2017;97(8):989-90. doi: 10.2340/00015555-2698.
  39. Renert-Yuval Y., Guttman-Yassky E. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. Ann Allergy Asthma Immunol. 2020;124(1):28-35. DOI: 10.1016/j. anai.2019.10.005.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2021

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies